Last reviewed 2026-04-22 · How we verify

BNX sublingual film

Orexo AB · Phase 3 active Small molecule

BNX sublingual film is a Partial mu-opioid receptor agonist Small molecule drug developed by Orexo AB. It is currently in Phase 3 development for Opioid use disorder maintenance treatment, Moderate to severe pain. Also known as: Suboxone film.

BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment.

BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment. Used for Opioid use disorder maintenance treatment, Moderate to severe pain.

At a glance

Generic name	BNX sublingual film
Also known as	Suboxone film
Sponsor	Orexo AB
Drug class	Partial mu-opioid receptor agonist
Target	Mu-opioid receptor (μ-OR)
Modality	Small molecule
Therapeutic area	Pain Management / Addiction Medicine
Phase	Phase 3

Mechanism of action

Buprenorphine is a partial mu-opioid receptor agonist that produces analgesia and reduces cravings in opioid use disorder. The sublingual film formulation allows rapid absorption through the oral mucosa, providing faster onset compared to tablets. As a partial agonist, it has a lower abuse potential and ceiling effect on respiratory depression compared to full opioid agonists.

Approved indications

Opioid use disorder maintenance treatment
Moderate to severe pain

Common side effects

Headache
Nausea
Constipation
Dizziness
Sweating
Insomnia

Key clinical trials

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BNX sublingual film CI brief — competitive landscape report
BNX sublingual film updates RSS · CI watch RSS
Orexo AB portfolio CI

Frequently asked questions about BNX sublingual film

What is BNX sublingual film?

BNX sublingual film is a Partial mu-opioid receptor agonist drug developed by Orexo AB, indicated for Opioid use disorder maintenance treatment, Moderate to severe pain.

How does BNX sublingual film work?

BNX is a buprenorphine sublingual film that binds to opioid receptors to provide analgesia and opioid dependence treatment.

What is BNX sublingual film used for?

BNX sublingual film is indicated for Opioid use disorder maintenance treatment, Moderate to severe pain.

Who makes BNX sublingual film?

BNX sublingual film is developed by Orexo AB (see full Orexo AB pipeline at /company/orexo-ab).

Is BNX sublingual film also known as anything else?

BNX sublingual film is also known as Suboxone film.

What drug class is BNX sublingual film in?

BNX sublingual film belongs to the Partial mu-opioid receptor agonist class. See all Partial mu-opioid receptor agonist drugs at /class/partial-mu-opioid-receptor-agonist.

What development phase is BNX sublingual film in?

BNX sublingual film is in Phase 3.

What are the side effects of BNX sublingual film?

Common side effects of BNX sublingual film include Headache, Nausea, Constipation, Dizziness, Sweating, Insomnia.

What does BNX sublingual film target?

BNX sublingual film targets Mu-opioid receptor (μ-OR) and is a Partial mu-opioid receptor agonist.

Drug class: All Partial mu-opioid receptor agonist drugs
Target: All drugs targeting Mu-opioid receptor (μ-OR)
Manufacturer: Orexo AB — full pipeline
Therapeutic area: All drugs in Pain Management / Addiction Medicine
Indication: Drugs for Opioid use disorder maintenance treatment
Indication: Drugs for Moderate to severe pain
Also known as: Suboxone film
Compare: BNX sublingual film vs similar drugs
Pricing: BNX sublingual film cost, discount & access